Aileron Therapeutics to Present at the Jefferies 2019 Healthcare Conference

Aileron Therapeutics Reports First Quarter 2019 Financial Results

Aileron Therapeutics to Report First Quarter 2019 Financial Results on May 8

Aileron Therapeutics Completes $26M Private Placement

Aileron Therapeutics Announces Pricing of $26M Private Placement

Aileron Therapeutics Appoints Kathryn Gregory as Chief Business Officer

Aileron Therapeutics Commences Enrollment in a Phase 2a Expansion Cohort for ALRN-6924 in Combination with Pfizer’s IBRANCE® (palbociclib) in Patients with MDM2-Amplified Cancers

Aileron Presents Interim ALRN-6924 Data from PTCL, MDS, and AML Clinical Trials at the 60th Annual American Society of Hematology Meeting

Aileron Enters Clinical Trial Collaboration with Pfizer to Evaluate ALRN-6924 in Combination with IBRANCE® (palbociclib) in MDM2-Amplified Cancers

Aileron Therapeutics Reports Third Quarter 2018 Financial Results